CHIRON CORPORATION AMENDED AND RESTATED BYLAWS INDEXChiron Corp • May 5th, 2003 • Pharmaceutical preparations
CHANGES IN THE NAME AND COMPOSITION OF THE NOMINATING COMMITTEE; AMENDMENT TO GOVERNANCE AGREEMENTGovernance Agreement • May 5th, 2003 • Chiron Corp • Pharmaceutical preparations
WHEREAS, Section 2.04 (a)(iv) of that certain Governance Agreement dated as of November 20, 1994, as amended (the "Governance Agreement"), between Chiron Corporation ("Chiron" or the "Company") and Novartis AG ("Novartis") as successor-in-interest to Ciba-Geigy Limited, requires the approval of Novartis of any change in the size or composition of any committee of the Board of Directors of Chiron;
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.Chiron Corp • May 5th, 2003 • Pharmaceutical preparations
Regulatory Filing, Development and Supply Agreement dated May 10, 1993 between Chiron Corporation and Schering AG (the "RFDS Agreement")
QuickLinks -- Click here to rapidly navigate through this documentChiron Corp • May 5th, 2003 • Pharmaceutical preparations • California
On behalf of the Board of Directors and all members of the Chiron community, I am very pleased to extend to you our offer to lead our Company, as President and Chief Executive Officer. Subject to your agreement, this letter sets forth the terms of your employment by Chiron.
AMENDMENT TO GOVERNANCE AGREEMENTGovernance Agreement • May 5th, 2003 • Chiron Corp • Pharmaceutical preparations
AMENDMENT TO GOVERNANCE AGREEMENT dated as of March 11, 2003 (this "Amendment") to the Governance Agreement dated as of November 20, 1994, as amended (the "Agreement"), by and between Chiron Corporation, a Delaware corporation ("Chiron"), and Novartis AG as successor in interest to Ciba-Geigy Limited ("Novartis").
